Minimal Residual Disease in Multiple Myeloma Ready for Prime Time?

被引：6

作者：

Mina, Roberto ^{[1
]}

Bonello, Francesca ^{[1
]}

Oliva, Stefania ^{[1
]}

机构：

[1] Univ Turin, Azienda Osped Univ Citta Salute & Sci Torino, Div Hematol, Myeloma Unit, Via Genova 3, I-10126 Turin, Italy

来源：

CANCER JOURNAL | 2021年 / 27卷 / 03期

关键词：

Endpoints; minimal residual disease (MRD); multiparameter flow cytometry (MFC); multiple myeloma (MM); next-generation sequencing (NGS); positron emission tomography; computed tomography (PET; CT); MULTIPARAMETER FLOW-CYTOMETRY; POSITRON EMISSION TOMOGRAPHY; STEM-CELL TRANSPLANTATION; NEXT-GENERATION FLOW; COMPLETE RESPONSE; MAINTENANCE THERAPY; SURVIVAL OUTCOMES; ONCOLOGY-GROUP; BONE-MARROW; DARATUMUMAB;

D O I：

10.1097/PPO.0000000000000519

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Minimal residual disease (MRD) techniques are essential to identify the small clonal fraction within and outside the bone marrow. In the last years, evidence regarding their prognostic role for the evaluation of the depth of response of current treatment strategies has grown rapidly. Consequently, MRD was incorporated in an increasing number of clinical trials for multiple myeloma patients, also as primary endpoint, and even to guide therapeutic choices. A robust correlation between MRD negativity and survival was established. Yet, several issues regarding MRD evaluation remain to be addressed: from the optimal and more cost-effective techniques for its assessment and its harmonization worldwide to its use in clinical practice to its impact on treatment modulation. This review focuses on the available evidence supporting the use of MRD status for the management of multiple myeloma patients and on open issues that still need an answer.

引用

页码：247 / 255

页数：9

共 82 条

[1] Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes [J].

Alsina, Melissa ;

Shah, Nina ;

Raje, Noopur S. ;

Jagannath, Sundar ;

Madduri, Deepu ;

Kaufman, Jonathan L. ;

Siegel, David S. ;

Munshi, Nikhil C. ;

Rosenblatt, Jacalyn ;

Lin, Yi ;

Jakubowiak, Andrzej ;

Jasielec, Jagoda ;

Timm, Alison ;

Turka, Ashley ;

Mao, Pingping ;

Martin, Nathan ;

Campbell, Timothy B. ;

Hege, Kristen ;

Bitter, Hans ;

Petrocca, Fabio ;

Berdeja, Jesus G. .

BLOOD, 2020, 136

[2]

Askeland FB., 2020, BLOOD, V136, P21

[3] Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study [J].

Attal, Michel ;

Richardson, Paul G. ;

Rajkumar, S. Vincent ;

San-Miguel, Jesus ;

Beksac, Meral ;

Spicka, Ivan ;

Leleu, Xavier ;

Schjesvold, Fredrik ;

Moreau, Philippe ;

Dimopoulos, Meletios A. ;

Huang, Jeffrey Shang-Yi ;

Minarik, Jiri ;

Cavo, Michele ;

Prince, H. Miles ;

Mace, Sandrine ;

Corzo, Kathryn P. ;

Campana, Frank ;

Le-Guennec, Solenn ;

Dubin, Franck ;

Anderson, Kenneth C. .

LANCET, 2019, 394 (10214) :2096-2107

[4]

Avet-Loiseau H., 17 INT MYEL WORKSH B

[5] Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR [J].

Avet-Loiseau, Herve ;

San-Miguel, Jesus ;

Casneuf, Tineke ;

Iida, Shinsuke ;

Lonial, Sagar ;

Usmani, Saad Z. ;

Spencer, Andrew ;

Moreau, Philippe ;

Plesner, Torben ;

Weisel, Katja ;

Ukropec, Jon ;

Chiu, Christopher ;

Trivedi, Sonali ;

Amin, Himal ;

Krevvata, Maria ;

Ramaswami, Priya ;

Qin, Xiang ;

Qi, Mia ;

Sun, Steven ;

Qi, Ming ;

Kobos, Rachel ;

Bahlis, Nizar J. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (10) :1139-+

[6] Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis [J].

Avet-Loiseau, Herve ;

Ludwig, Heinz ;

Landgren, Ola ;

Paiva, Bruno ;

Morris, Chris ;

Yang, Hui ;

Zhou, Kefei ;

Ro, Sunhee ;

Mateos, Maria-Victoria .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (01) :E30-E37

[7]

Avet-Loiseau H, 2019, J CLIN ONCOL, V37

[8] External Validation of Diffusion Weighted Whole Body MRI (DW-MRI) Response Assessment Category (RAC) Criteria Proposed By the Myeloma Response Assessment and Diagnosis System (MY-RADS) Imaging Recommendations: Prognostic Role of Imaging Response after Transplant in Multiple Myeloma and Comparison with MRD Evaluation By Flow Cytometry [J].

Belotti, Angelo ;

Ribolla, Rossella ;

Cancelli, Valeria ;

Villanacci, Alberta ;

Angelini, Valentina ;

Ferrari, Samantha ;

Peli, Annalisa ;

Cattaneo, Chiara ;

Chiarini, Marco ;

Grazioli, Luigi ;

Rossi, Giuseppe ;

Tucci, Alessandra .

BLOOD, 2020, 136

[9] Poor Prognosis of Multiple Myeloma Predicted By High Levels of Circulating Plasma Cells Is Independent from Other High-Risk Features but Is Modulated By the Achievement of Minimal Residual Disease Negativity [J].

Bertamini, Luca ;

Grasso, Mariella ;

D'Agostino, Mattia ;

Pascarella, Anna ;

Tosi, Patrizia ;

Monaco, Federico ;

Pisani, Francesco ;

Bertazzoni, Paola ;

Gilestro, Milena ;

Capra, Andrea ;

Galieni, Piero ;

Annibali, Ombretta ;

Pavone, Vincenzo ;

Molica, Stefano ;

Ronconi, Sonia ;

Tacchetti, Paola ;

Musto, Pellegrino ;

Gay, Francesca ;

Boccadoro, Mario ;

Oliva, Stefania .

BLOOD, 2020, 136

[10] Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time? [J].

Bolli, Niccolo ;

Genuardi, Elisa ;

Ziccheddu, Bachisio ;

Martello, Marina ;

Oliva, Stefania ;

Terragna, Carolina .

FRONTIERS IN ONCOLOGY, 2020, 10

← 1 2 3 4 5 6 7 8 9 →